Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation
Status:
Completed
Trial end date:
2003-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the response rate of patients with refractory,
relapsed or poor risk AML expressing FLT-3 activating mutations, when administered CEP-701 at
a dosage of 60 mg 2 times a day.